Quantum Biopharma (QNTM) Free Cash Flow (2019 - 2026)
Quantum Biopharma (QNTM) posted Free Cash Flow of $1.3 million for Q1 2026, up 523.27% sequentially from -$305598.0 in Q4 2025, and up 188.54% YoY from $448281.6 in Q1 2025.
Quantum Biopharma (QNTM) Free Cash Flow (2019 - 2026) Analysis & Trends
Quantum Biopharma has reported Free Cash Flow for 8 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 188.54% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$350748.0 (up 94.51% YoY) and the FY2025 annual result came in at -$8.2 million, down 19.79% from the prior year.
- Free Cash Flow improved to $1.3 million in Q1 2026 per QNTM's latest filing, from -$305598.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at $9.4 million in Q2 2022 and troughed at -$50.6 million in Q4 2022.
- A 5-year average of -$2.5 million and a median of -$502045.0 in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow sank 31491.93% in 2025, then surged 188.54% in 2026.
- Over 5 years, Free Cash Flow stood at -$50.6 million in 2022, then surged by 98.53% to -$744500.0 in 2023, then plunged by 480.41% to -$4.3 million in 2024, then surged by 92.93% to -$305598.0 in 2025, then surged by 523.27% to $1.3 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $1.3 million, -$305598.0, and -$836595.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - | -1.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.79 Mn |
| Jun 30, 2026 | -1.79 Mn |
| Mar 31, 2026 | 1.29 Mn |
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | -305,598.00 |
| Dec 31, 2025 | -305,598.00 |
| Sep 30, 2025 | -836,595.00 |
| Sep 30, 2025 | -836,595.00 |
| Jun 30, 2025 | -502,045.00 |
| Jun 30, 2025 | -502,045.00 |
| Mar 31, 2025 | -1.46 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | -4.32 Mn |
| Dec 31, 2024 | -4.32 Mn |
| Sep 30, 2024 | 2,665.00 |
| Sep 30, 2024 | 2,665.00 |
| Jun 30, 2024 | -606,704.00 |
| Jun 30, 2024 | -606,704.00 |
| Mar 31, 2024 | -1.95 Mn |
| Mar 31, 2024 | -1.95 Mn |